EXPRESSION OF ONCOGENES & IGA GENES IN TRANSFORMED CELLS
Project Number5R01CA036355-02
Contact PI/Project LeaderSONENSHEIN, GAIL E
Awardee OrganizationBOSTON UNIVERSITY MEDICAL CAMPUS
Description
Abstract Text
In many Balb/c mouse myeloma cell lines the c-myc oncogene normally located
on chromosome 15 is often translocated to a H chain constant region locus
on chromosome 12. In the majority of myelomas studied, the translocation
of c-myc is to the alpha constant region sequence (C-alpha) of the H chain
"non-productive" gene (the mRNA coding strand of DNA for the c-myc gene is
on the anti-sense strand for the C-alpha gene). While unrearranged C-alpha
alleles are transcriptionally silent, C-alpha genes to which the c-myc
oncogene has translocated are transcriptionally active. Several discrete
cytoplasmic RNA species hybridizing to a alpha-C region probe can be
detected. Some of these appear to be transcribed from the C-alpha sense
strand. In a mouse myeloma MOPC 315 variant line (V-1), which has lost the
alpha-H chain gene, cotranscription of c-myc and C-alpha sequences has been
detected. In this application the products of the c-myc-C-alpha
transcriptional unit in V-1 cells will be examined. A genomic clone of
this locus has been isolated. The initiation and termination sites will be
mapped, and the products of transcription analyzed. The sizes of C-alpha
and c-myc proteins will be determined using hybrid-selection and cell-free
translation in a rabbit reticulocyte system. The steps in synthesis and
processing of C-alpha proteins will be determined. Finally, the possible
relationship of the translocation of c-myc to C-alpha to the loss of normal
immunosuppression of cell growth will be studied. Methods will include
tissue culture, RNA and DNA blot hybridization, DNA sequencing, cell-free
translation, and acrylamide and agarose gel electrophoresis. The
experiments will characterize the RNA and protein products of the c-myc
oncogene-C-alpha gene locus and help define their possible roles in the
neoplastic transformation of myeloma cells. (X)
No Sub Projects information available for 5R01CA036355-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01CA036355-02
Patents
No Patents information available for 5R01CA036355-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01CA036355-02
Clinical Studies
No Clinical Studies information available for 5R01CA036355-02
News and More
Related News Releases
No news release information available for 5R01CA036355-02
History
No Historical information available for 5R01CA036355-02
Similar Projects
No Similar Projects information available for 5R01CA036355-02